Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Notice to attend the extraordinary general meeting of Diagonal Bio AB

Shareholders in Diagonal Bio AB, 559248-8984, are hereby invited to attend an extraordinary general meeting on Tuesday, 2nd of April, 2024, at 13:00 CET at The Spark, conference room 10, Medicon Village, Scheeletorget 1 Lund.Right to Participate and Notification Shareholders who wish to participate at the extraordinary general meeting must: · be registered as a shareholder in the share register maintained by Euroclear Sweden AB on Thursday, March 21[st], 2024, and · notify the company no later than Monday, March 25[th], 2024, by email to egm@diagonalbio.com. Notifications can

Read original

The Board of Directors decides on a preferential rights issue of units in order to finance future development

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION WHERE THIS PRESS RELEASE IS DISTRIBUTABLE WOULD BE ILLEGAL OR REQUIRE ADDITIONAL ACTIONS THAN SUCH ACTIONS RESULTING FROM SWEDISH LAW. SEE THE “IMPORTANT INFORMATION” SECTION AT THE END OF THIS PRESS RELEASE.The Board of Directors of Diagonal Bio AB ("Diagonal Bio" or the "Company") has today, on February 28, 2024, resolved to carry out an issue of units

Read original

#24-75 Delisting of Derivatives from NGM

Information about certain derivatives that will be delisted from NGM.For more details, see attached files. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for

#24-74 Listing of Derivatives at NGM

Information about various derivatives that will be listed at NGM.For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGMNordic Growth Market NGM AB (NGM) is an authorized stock exchange with operations in Sweden, Norway, Denmark and Finland. The exchange is a wholly-owned subsidiary of Boerse Stuttgart, the leading retail exchange in Germany. NGM offers a complete marketplace for exchange traded products and provides a complete platform for companies

Diagonal Bio AB Year-end Report 2023

“Looking back at 2023, I am proud to point out the significant steps we have made in our development, including the key achievements such as the CE-marking of LAMPlify® according to Low Voltage Directive (LVD) 2006/95/ EC. A highlight of our fourth quarter was the commencement of LAMPlify® commercialisation.” says, Karin Wehlin, interim CEO Diagonal Bio AB.Summary of Year-end Report 2023 2023-10-01 — 2023-12-31 (October — December) • Net sales amounted to 23 KSEK (0 KSEK), capitalised development contributed with 405 KSEK (846 KSEK), while other operating income amounted to 7 KSEK (3

Read original

Arctic Bioscience – Treatment start for 519 patients in the HeROPA-study

With reference to the stock exchange announcement from 17. January 2024 which reported that the HeROPA phase IIb clinical trial in mild-to-moderate psoriasis was fully recruited with the planned 519 patients, Arctic Bioscience are pleased to report that 519 patients are now dosed with the Investigational Medicinal Product HRO350 or placebo. After all patients have been dosed for 6 months, the primary endpoint will be read out.The HeROPA trial is randomized, double blind and placebo controlled, investigating the efficacy and safety of the novel, oral drug candidate HRO350 for the treatment

Bulletin from Sivers Semiconductors AB (publ)’s Extraordinary General Meeting on 28 February 2024

The Extraordinary General Meeting in Sivers Semiconductors AB (publ) (the “Company”) has been held on 28 February 2024 and in particular the following decisions were resolved.The general meeting resolved that the board of directors would, until the end of the next annual general meeting, consist of five members elected by the general meeting without deputies. Further, the general meeting resolved that the annual general meeting’s resolution from 25 May 2023 on remuneration amounting to a total of SEK 2,520,000, of which SEK 1,050,000 to the chairman of the board and SEK 350,000 to each of

Replacement - Update to 2024 Financial Calendar

The following amendments have been made to the 'Update to Faron’s Financial Calendar for 2024' announcement released on 27 February 2024 at 1:00 p.m. EST / 6:00 p.m. GMT / 8:00 p.m. EET under RNS No 6663E.   -          Replacement wording included. -          Change of date of the Company’s AGM and publication of 2023 financial statement. -          Reasoning for change of date of publishing financial statement release for the full year 2023 and Annual Report 2023, including financial statements for the full year. -          Wording on defined terms.   All other details

1st Quarter Results

Regulatory Announcement Royal Bank of Canada February 28, 2024 First Quarter 2024 Earnings Release The First Quarter 2024 Earnings Release has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism To view the full document, please paste the following URL into the address bar of your browser. First Quarter 2024 Earnings Release dated February 28, 2024 http://www.rns-pdf.londonstockexchange.com/rns/8401E_1-2024-2-28.pdf A copy of the First Quarter 2024 Earnings Release

1st Quarter Results

Regulatory Announcement Royal Bank of Canada February 28, 2024 First Quarter Results The First Quarter 2024 Report to Shareholders has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism To view the full document, please paste the following URL into the address bar of your browser. First Quarter 2024 Report to Shareholders dated February 28, 2024 http://www.rns-pdf.londonstockexchange.com/rns/8407E_1-2024-2-28.pdf A copy of the First Quarter 2024 Report to

Newsletter focusing on the sales launch of Zeqmelit®

The sales launch of Zeqmelit® is the theme of AcuCort's newsletter #3, which is being published today.The first commercial order of Zeqmelit® is the featured topic of the newsletter. Jonas Jönmark, CEO of AcuCort, discusses how the company is working to support sales efforts and prepare for the launch. The newsletter can be read via the following link: https://mailchi.mp/acucort/acucort-newsletter-february2024 To subscribe, register here: https://www.acucort.se/en/#mailchimp-module

Nordic Mining ASA: Mandatory notification of trade by close associate of primary insider

Exman AS, a closely associated enterprise of Jens Gisle Schnelle, Interim Chief Financial Officer and primary insider in Nordic Mining ASA, has today 28 February 2024 purchased 700,000 shares in Nordic Mining ASA at a price of NOK 0.7176 per share. Following this transaction, Jens Gisle Schnelle and closely related parties hold 700,000 shares in Nordic Mining ASA. For more information see the attached mandatory notification of trade. Oslo, 28 February 2024Nordic Mining ASA This information is subject to disclosure requirements set out in the Market Abuse Regulation EU 596/2014

New top ranking for Karolinska University Hospital in global hospital ranking

Karolinska once again achieves a prominent position in Newsweek magazine's ranking World's Best Hospitals. For the fifth year in a row, the hospital is in the top 10 and ranks seventh in the world.Newsweek's ranking is the only worldwide comparison made. It's based on four data sources: · Recommendations from experts in the health sector, such as doctors and managers. 85,000 experts from around the world were invited, and responses were provided by a large number of them. · Results of patient surveys, for example regarding treatment and information. · Quality outcomes, such as

Best Home Insurance in Ontario 2024: A Comprehensive Guide

[Compare home insurance companies] Home insurance stands as a crucial shield for Ontario homeowners, safeguarding their property and assets against potential losses or disasters. Given the plethora of choices, finding the ideal home insurance policy tailored to your specific requirements can prove challenging. This comprehensive guide will help you understand the various coverage options and factors to consider, as well as provide tips for finding the best home insurance in Ontario. Whether you're a first-time homebuyer or an experienced homeowner, this guide will give you the

Letter from the CEO: CS MEDICA's 2024 Progress Report

CS MEDICA Provides Insights on Continued Growth and Strategic Health.As a follow-up to our Annual Report, we're still navigating through the complexities of our industry as a scale-up MedTech and the challenges that come our way. I want to address some concerns that have been raised regarding CS MEDICA's financial capacity and the impact these factors may have on our growth and overall company health.   Despite the hurdles, our strategic focus and operational adjustments yield tangible results. We are witnessing an uplift in customer acquisition, with registrations and patents increasing

Atria buys two pig farms in Estonia

Atria Estonia invests in local pork production in Estonia and buys two pig farms in Southern Estonia, Veelikse village, Mulgimaa. The consumption of pork in Estonia has been stable, and with the acquisition, Atria aims to ensure the supply of domestic pork in the future as well. − In Estonia, pork self-sufficiency is about 70 percent, and it is very important for us to be able to offer domestic pork to consumers. After this acquisition, Atria owns 6 pig farms in Estonia, with an annual production of about 5 million kilos, says Atria Estonia’s Managing Director Olle Horm. − We are

Grant of warrants and adjustments to terms of existing retention program

MapsPeople A/S I Grant of warrants and adjusted warrants terms Company Announcement No. 2 - 2024 Aalborg, February 28, 2024 Grant of warrants In order to implement a retention and incentive program, the board of directors of MapsPeople today exercised part of its authorization in section 4.16 of MapsPeople’s articles of association to issue a total of 550,000 warrants. The warrants were issued to Christian Læsø and one key employee. The exercise price is fixed at DKK 1.19 per share corresponding to the subscription price at the latest private placement in December 2023 as

Neonode Reports 2023 Financial Results

STOCKHOLM, SWEDEN, February 28, 2024 — Neonode Inc. (NASDAQ: NEON) today reported financial results for the fiscal year ended December 31, 2023.FINANCIAL SUMMARY FOR THE FISCAL YEAR ENDED DECEMBER 31, 2023: · Revenue of $4.4 million, a decrease of 21.5% compared to the prior year. · Operating expenses of $10.7 million, an increase of 4.9% compared to the prior year. · Net loss of $10.1 million, or $0.66 per share, compared to $4.9 million, or $0.36 per share, for the prior year. · Cash used by operations of $6.3 million, compared to $6.8 million for the prior year. · Cash

Aptahem’s scientific manuscript now published in the journal Cells

Aptahem announced on the 27 February 2024 that the company’s scientific manuscript had been accepted for publication in the journal Cells. Today, the 28 February 2024, the paper has been published.The title of the manuscript is ”Therapeutic effects of a novel aptamer on coronaviral infection induced lung injury and systemic inflammatory responses” and can be accessed via this link . The manuscript describes the results of the preclinical studies performed in SARS Corona virus models in collaboration with the research group in Toronto, which indicate

Holding(s) in Company

TR-1: Standard form for notification of major holdings [][][][][][][]NOTIFICATION OFMAJOR HOLDINGS(tobe sent to therelevant issuerandto the FCA inMicrosoft Wordformatif possible) [i] 1a. Identity of Oscillate Plcthe issuer or theunderlying issuerof existingsharesto which votingrights areattached[ii]:1b. Pleaseindicate if theissuer isa non-UK issuer (please markwithan “X” ifappropriate)Non-UK issuer2. Reason for thenotification(please mark theappropriate boxorboxes with an“X”)An

AcuCort presents at three events for investors

AcuCort will participate in three investor presentations during March. CEO Jonas Jönmark will summarize the latest news and discuss the launch of the oral film Zeqmelit®.What does the process look like regarding the launch of the oral film Zeqmelit® and how will the company evolve with the transition from a research company to a pharmaceutical company? These are the key areas that will be addressed when AcuCort's CEO Jonas Jönmark participates in Stora Aktiedagen, Invest Live, and Stockholm Corporate Finance Capital Markets Days Life Science in the near future. Information about the

Techstep signs strategic partnership agreement with devicenow for Lifecycle Portal

Techstep has entered into a strategic partnership agreement with devicenow, a global provider of subscription-based IT devices, to introduce Lifecycle Portal to a wider customer base worldwide. Lifecycle Portal is Techstep’s proprietary software for automated device lifecycle management. It enables customers to control every lifecycle event of their device estate from purchase and onboarding to offboarding and recycling. Lifecycle Portal allows customers to free up time, reduce cost, and adopt more sustainable practices in device handling. Devicenow, a German-based company and part of

There are no items matching the current filter
There are no more items matching the current filter
Back to top